PIK3CA and neoplasm: Ipatasertib is being developed for the treatment of cancers in which PI3K/AKT pathway activation may be relevant for tumor growth or therapeutic resistance, and has demonstrated PI3K/AKT pathway inhibition in preclinical studies [10–12].